呋喃-2-磺酰氯 | 52665-48-2

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物 - 羧酸酰卤化物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 杂芳族化合物
• 中文名称: 呋喃-2-磺酰氯
• 英文名称: furan-2-sulfonyl chloride
• 英文别名: 2-furansulfonyl chloride；2-furanylsulfonyl chloride
• CAS: 52665-48-2
• 化学式: C₄H₃ClO₃S
• mdl: MFCD06658968
• 分子量: 166.585
• InChiKey: IEKOSPNJXYCZHY-UHFFFAOYSA-N

物化性质

• 沸点：
  79 °C
• 密度：
  1.529±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  55.7
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  C,Xi
• 安全说明：
  S26
• 危险类别码：
  R36
• 海关编码：
  2932190090
• 包装等级：
  II
• 危险类别：
  8
• 危险性防范说明：
  P260,P264,P280,P301+P330+P331,P303+P361+P353,P304+P340,P305+P351+P338,P310,P321,P363,P405,P501
• 危险品运输编号：
  3265
• 危险性描述：
  H314

SDS

Name:	Furan-2-sulfonyl chloride Material Safety Data Sheet
Synonym:	None Known
CAS:	52665-48-2

Section 1 - Chemical Product MSDS Name:Furan-2-sulfonyl chloride Material Safety Data Sheet
Synonym:None Known

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
52665-48-2	Furan-2-sulfonyl chloride	97+%	unlisted

Hazard Symbols: C
Risk Phrases: 14 22 29 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Reacts violently with water. Harmful if swallowed. Contact with water liberates toxic gas. Causes burns.Water-reactive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Chronic exposure may cause effects similar to those of acute exposure.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately. Do NOT allow victim to rub eyes or keep eyes closed.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
If swallowed, do NOT induce vomiting. Get medical aid immediately.
If victim is fully conscious, give a cupful of water. Never give anything by mouth to an unconscious person.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If breathing is difficult, give oxygen. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion. Water Reactive. Material will react with water and may release a flammable and/or toxic gas.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide. DO NOT USE WATER! Contact professional fire-fighters immediately.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Avoid runoff into storm sewers and ditches which lead to waterways. Clean up spills immediately, observing precautions in the Protective Equipment section. Provide ventilation. Do not expose spill to water.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not allow water to get into the container because of violent reaction. Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Keep container tightly closed. Do not ingest or inhale. Use only in a chemical fume hood. Discard contaminated shoes. Keep from contact with moist air and steam.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Keep away from water. Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use explosion-proof ventilation equipment. Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 52665-48-2: Personal Protective Equipment Eyes: Wear chemical splash goggles and face shield.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: Pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 79 - 81 deg C @10mm Hg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H3ClO3S
Molecular Weight: 166.58

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Combines vigorously or explosively with water. Reacts with water to form hydrogen chloride, a toxic and corrosive gas.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Water, strong oxidizing agents, strong bases.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, oxides of sulfur, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 52665-48-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Furan-2-sulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION
Ecotoxicity:
Fish: Pseudomonas putida:

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S.
Hazard Class: 8 (4.3)
UN Number: 3265
Packing Group: II
IMO
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S.
Hazard Class: 8 (4.3)
UN Number: 3265
Packing Group: II
RID/ADR
Shipping Name: CORROSIVE LIQUID, WATER-REACTIVE, N.O.S.
Hazard Class: 8 (4.3)
UN Number: 3265
Packing group: II

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 14 Reacts violently with water.
R 22 Harmful if swallowed.
R 29 Contact with water liberates toxic gas.
R 34 Causes burns.
Safety Phrases:
S 23 Do not inhale gas/fumes/vapour/spray.
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 30 Never add water to this product.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 52665-48-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 52665-48-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 52665-48-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  呋喃-2-磺酰氯 在 hydrazine hydrate 作用下， 以 四氢呋喃 为溶剂， 反应 1.0h， 生成 thiophene-2-sulfonohydrazide
  参考文献：
  名称：

  Development of novel NLRP3-XOD dual inhibitors for the treatment of gout

  摘要：

  Gout is a crystalline-related arthropathy caused by the deposition of monosodium urate (MSU). Acute gouty arthritis is the most common first symptom of gout. Studies have shown that NOD-like receptor protein 3 (NLRP3) inflammasome as pattern recognition receptors can be activated by uric acid crystallization, triggering immune inflammation and causing acute gouty arthritis symptoms. Currently, the treatment of gout mainly includes two basic methods: reducing uric acid and alleviating inflammation. In this paper, 22 novel benzoxazole and benzimidazole derivatives were synthesized from deoxybenzoin oxime derivatives. These compounds have good inhibitory effects on NLRP3 and XOD screened by our research group in the early stage. The inhibitory activities of XOD and NLRP3 and their derivatives were also screened. Notably, compound 9b is a multi-targeting inhibitor of NLRP3 and XOD with excellent potency in treating hyperuricemia and acute gouty arthritis.

  DOI：

  10.1016/j.bmcl.2019.126944
• 作为产物：
  描述：

  呋喃 在 叔丁基锂 、 双(二氧化硫)-1,4-二氮杂双环[2.2.2]辛烷加合物 、 N-氯代丁二酰亚胺 作用下， 以 四氢呋喃 、 正戊烷 为溶剂， 反应 1.25h， 以14.4%的产率得到呋喃-2-磺酰氯
  参考文献：
  名称：

  含杂环的 Noyori-Ikariya 催化剂用于酮的不对称转移氢化

  摘要：

  描述了一系列 N-(杂环磺酰基)-官能化 Noyori-Ikariya 催化剂的合成。这些配合物是通过 C2-对称 1,2-二苯基乙烯-1,2-二胺 (DPEN) 的短序列制备的，并通过包括 X 射线晶体学在内的一系列方法进行表征。该配合物是一系列苯乙酮衍生物不对称转移氢化 (ATH) 的活性催化剂，在大多数情况下得到高 ee 的产物，对邻位取代的苯乙酮具有显着的良好效果。

  DOI：

  10.1039/d2dt02411j

文献信息

• Benzene Sulfonamide Thiazole and Oxazole Compounds
  申请人：Adams Jerry Leroy

  公开号：US20090298815A1

  公开（公告）日：2009-12-03

  The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents.

  本发明提供了噻唑磺胺和噁唑磺胺化合物，含有这些化合物的组合物，以及用作药物制剂的制备方法和使用方法。
• Biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
  申请人：——

  公开号：US20020095041A1

  公开（公告）日：2002-07-18

  Biphenylsulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, bicyclic or tricyclic carbon or heterocyclic ring biphenylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.

  提供了二苯基磺胺类化合物和调节或改变内皮素家族肽活性的方法。具体包括使用双环或三环碳或杂环环二苯基磺胺类化合物的方法，通过将该磺胺类化合物与内皮素受体接触来抑制内皮素肽与内皮素受体的结合。还提供了通过给予有效剂量的这些磺胺类化合物或其前药来治疗内皮素介导的疾病的方法，这些化合物能够抑制或增加内皮素的活性。
• SULFONAMIDE DERIVATIVE AND MEDICINAL USE THEREOF
  申请人：AJINOMOTO CO., LTD.

  公开号：US20150051395A1

  公开（公告）日：2015-02-19

  Provided are sulfonamide derivatives of a specific chemical structure in which a sulfonamide group having, as a substituent, a phenyl group or a heterocyclic group having a hetero atom(s) as a constituent element(s) is present at its terminal, and pharmaceutically acceptable salts thereof. These compounds are novel compounds having excellent α4 integrin-inhibitory action.

  提供的是具有特定化学结构的磺酰胺衍生物，在其末端有一个带有苯基或含杂原子的杂环基团作为取代基的磺酰胺基团，以及药用可接受的盐。这些化合物是具有卓越的α4整合素抑制作用的全新化合物。
• SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：Ajinomoto Co., Inc.

  公开号：US20160244451A1

  公开（公告）日：2016-08-25

  Provided is a sulfonamide derivative represented by the following general formula (1) and having an α4 integrin inhibitory effect with high selectivity with a low effect on α4β1 and a high effect on α4β7, or a pharmaceutically acceptable salt thereof (in the general formula (1), A, B, D, E, R 41 , and a to h are as described in the description).

  提供的是一种磺酰胺衍生物，其具有以下通式(1)表示，并具有对α4整合素抑制效果的高选择性，对α4β1影响小，对α4β7影响大，或其药用可接受盐（在通式(1)中，A、B、D、E、R 41 和a至h如描述中所述）。
• Exploration of pyrrole derivatives to find an effective potassium-competitive acid blocker with moderately long-lasting suppression of gastric acid secretion
  作者：Haruyuki Nishida、Ikuo Fujimori、Yasuyoshi Arikawa、Keizo Hirase、Koji Ono、Kazuo Nakai、Nobuhiro Inatomi、Yasunobu Hori、Jun Matsukawa、Yasushi Fujioka、Akio Imanishi、Hideo Fukui、Fumio Itoh

  DOI：10.1016/j.bmc.2017.04.034

  日期：2017.7

  drug, we tried to optimize the duration of action of the pyrrole derivative. Among the compounds synthesized, fluoropyrrole derivative 20j, which has a 2-F-3-Py group at position 5, fluorine atom at position 4, and a 4-Me-2-Py sulfonyl group at the first position of the pyrrole ring, showed potent gastric acid-suppressive action and moderate duration of action in animal models. On the basis of structural

  为了发现一种新型的优异的钾竞争性酸阻滞剂（P-CAB），可以完全克服质子泵抑制剂（PPI）的局限性，我们测试了以吡咯衍生物1为前导化合物的各种方法。作为识别新的有效药物的综合方法的一部分，我们试图优化吡咯衍生物的作用持续时间。在合成的化合物中，氟吡咯衍生物20j，它在5位具有2-F-3-Py基团，在4位具有氟原子，并且在吡咯环的第一位具有4-Me-2-Py磺酰基，显示出有效的胃酸抑制作用，并且在动物模型中的作用持续时间适中。上的结构的性质，包括在pH 7.4相比，这些先前优化化合物的稍大Çlog P值（1.95），更大的日志d值（0.48），和相当类似的pKa值（8.73）的基础2a中，化合物20J是假定单次给药后会迅速转移到胃中，并在胃中有适度的滞留时间。因此，化合物20j被选作具有持续较长作用时间的新型有前途的P-CAB。